Albert David profit and loss

Latest FY26

Revenue: ₹334cr−3.5% on FY25
EBITDA: ₹5.5cr+80.6% on FY25
Net profit: −₹1.5cr₹17.2 cr in FY25
EPS: −₹2.62₹30.14 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	364	334	346	362	342	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	13.4	7.5	29.6	57.6	15.4
	378	341	375	420	357
	65.0	59.9	70.2	63.9	63.5
	51.5	49.0	60.5	64.3	64.1
	8.3	5.0	−14.3	−1.8	−4.6
	99.6	102	109	88.4	81.1
	2.6	2.6	0.4	0.3	0.5
	9.7	9.8	7.0	6.8	8.5
	113	112	117	101	93.1
	350	341	350	323	306
	26.8	5.5	3.0	46.9	44.3
	17.1	−4.3	−3.9	40.1	35.8
Profit
	27.9	0.5	25.2	97.3	50.7
	27.9	0.5	25.2	97.3	50.7
	4.5	3.3	5.9	15.8	16.0
	0.8	−1.3	2.1	6.1	−1.4
	5.3	2.0	8.0	21.9	14.6
	22.6	−1.5	17.2	75.4	36.2
	22.6	−1.5	17.2	75.4	36.2
	2.6	3.4	−1.1	1.1	1.1
	25.1	1.9	16.1	76.5	37.2
Per share
	₹39.53	−₹2.62	₹30.14	₹132.15	₹63.39
	₹39.53	−₹2.62	₹30.14	₹132.15	₹63.39
Other comprehensive income — detail
	2.6	3.4	−1.1	—	—
	3.3	4.5	−0.4	1.1	1.1
	0.8	1.1	0.7	—	—
	—	—	—	−0.0	0.0
Per share — as-filed variants
	₹39.53	−₹2.62	₹30.14	₹132.15	₹63.39
	₹39.53	−₹2.62	₹30.14	₹132.15	₹63.39
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	240	220	229	236	218
	65.8%	65.9%	66.4%	65.1%	64.0%
Adjusted (ex-exceptional items) — derived
	27.9	0.5	25.2	97.3	50.7
	22.6	−1.5	17.2	75.4	36.2
	₹39.53	−₹2.62	₹30.14	₹132.15	₹63.39

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

ALBERTDAVD₹772.00

Albert David Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersVALIANTLAB HALEOSLABS ZIMLAB MEDICO MEDICAMEQ ANUHPHR AHCL WANBURYMcap ₹441 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	341.6	362.5	345.8	333.6	364.4
Other Income	15.4	57.6	29.6	7.5	13.4
Total Income	357.0	420.0	375.3	341.1	377.7
Expenses
+ Cost of Materials Consumed	63.5	63.9	70.2	59.9	65.0
+ Purchases of Stock-in-Trade	64.1	64.3	60.5	49.0	51.5
+ Changes in Inventories	-4.6	-1.8	-14.3	5.0	8.3
+ Employee Benefit Expense	81.1	88.4	109.0	102.5	99.6
+ Finance Costs	0.5	0.3	0.4	2.6	2.6
+ Depreciation & Amortisation	8.5	6.8	7.0	9.8	9.7
+ Other Expenses	93.1	100.8	117.4	111.8	113.2
Total Expenses	306.2	322.7	350.1	340.5	349.9
EBITDA	44.3	46.9	3.0	5.5	26.8
EBIT	35.8	40.1	-3.9	-4.3	17.1
Profit
PBT before Exceptional Items	50.7	97.3	25.2	0.5	27.9
Pretax Income	50.7	97.3	25.2	0.5	27.9
+ Current Tax	16.0	15.8	5.9	3.3	4.5
+ Deferred Tax	-1.4	6.1	2.1	-1.3	0.8
Tax Expense	14.6	21.9	8.0	2.0	5.3
Net Income	36.2	75.4	17.2	-1.5	22.6
+ Net Income — Continuing Ops	36.2	75.4	17.2	-1.5	22.6
+ Other Comprehensive Income	1.1	1.1	-1.1	3.4	2.6
Total Comprehensive Income	37.2	76.5	16.1	1.9	25.1
Per Share
Basic EPS	63.39	132.15	30.14	-2.62	39.53
Diluted EPS	63.39	132.15	30.14	-2.62	39.53
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-1.1	3.4	2.6
+ Items NOT to be Reclassified to P&L	1.1	1.1	-0.4	4.5	3.3
+ Tax on Items NOT to be Reclassified	—	—	0.7	1.1	0.8
+ Tax on Items NOT to be Reclassified — alt tag	0.0	-0.0	—	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	63.39	132.15	30.14	-2.62	39.53
Diluted EPS — Continuing Operations	63.39	132.15	30.14	-2.62	39.53
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	218.5	236.1	229.5	219.7	239.6
Gross Margin %	63.96	65.13	66.37	65.87	65.76
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	50.7	97.3	25.2	0.5	27.9
Net Income Adj (tax-effected)	36.2	75.4	17.2	-1.5	22.6
EPS Adj	63.39	132.15	30.14	-2.62	39.53
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	5.7	5.7	5.7	5.7	5.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.